October 16, 2018
OICR offers new CT calibration service as part of its Collaborative Research Resources portfolio
Using imaging devices to help make treatment decisions in the clinic requires rigorous testing, quality assurance and routine calibration of the imaging machinery. These standards are especially important when the imaging technology is novel or unique, such as in the case of perfusion imaging – a relatively new technique used to diagnose a cancer’s stage by showing how blood flows through the tumour.
September 25, 2018
Breast cancer radiotherapy in a single visit provides more convenient option to patients, reduces burden of therapy
Cross-Canada research team moves image-guided ultrasound system into clinical development
Traditional breast cancer radiation treatment requires multiple hospital visits over a period of weeks or months, which may be onerous to patients who live far from hospitals or in remote communities. An alternative radiotherapy technique, Permanent Breast Seed Implantation (PBSI), requires only a single hospital visit, but it involves the implantation of multiple small radioactive metal pellets into the breast of the patient within millimetres of a target. The procedure to administer this treatment is difficult to plan and complex to execute – impeding the adoption of PBSI in the clinic.
September 13, 2018
Sunnybrook researchers develop new magnetic resonance imaging methods to help differentiate between aggressive and non-aggressive prostate cancers
Current needle biopsy techniques have limited accuracy in detecting prostate cancer and determining the tumour’s aggressiveness. New methods are needed to better detect and characterize prostate cancer so that each patient can get the treatment that is most appropriate for them.
August 2, 2018
The Centre for Probe Development and Commercialization (CPDC) awarded $10.5 million to expand molecular imaging probe work in Ontario
Translating new scientific discoveries into products and moving those products to the market is a challenging process. This is especially the case for highly-regulated medical products such as radiopharmaceuticals – a special class of drugs that are used to accurately diagnose and treat diseases. Over the past decade, the CPDC in Hamilton has been bridging the gap between the innovation and commercialization of radiopharmaceuticals in Ontario and, in turn, reaping benefits for patients and the province’s economy.
August 9, 2017
The Centre for Imaging Technology Commercialization (CIMTEC) has appointed Mr. Justin Leushner as Chief Executive Officer. CIMTEC was established to accelerate the development of medical imaging technology and commercialize new technologies. Leushner brings extensive experience in both the private and public sectors. Most recently he was the Vice President at the TechAlliance of Southwestern Ontario, where he and his team worked with more that 300 companies in the region.
March 8, 2017
In London, OICR leaders discussed cancer research advancements being made in the city. How can OICR help further translate these breakthroughs to patients?
Ontario’s wealth of cancer research expertise is not limited to one city or region. Innovations from researchers and clinician-scientists across the province are changing the approach to cancer worldwide. London is one of Ontario’s major cancer research nodes and boasts a particular strength in developing medical imaging technology. The city is home to the Lawson Health Research Institute, Robarts Research Institute and the Centre for Imaging Technology Commercialization. Life science and biotechnology research is the source of $1.5 billion in economic activity for the city annually.
September 16, 2016
Photo-thermal therapy, a type of treatment that uses light and heat to destroy cancer cells, has shown great promise, but is still not widely used. A group in Toronto recently developed a technology that may go a long way in making the use of this type of therapy more effective and common.
June 1, 2016
Dr. Laurence Klotz of Sunnybrook Health Sciences Centre is a world leader in the field of prostate cancer research. He has been a champion of active surveillance (also known as watchful waiting) for over 20 years, an approach to prostate cancer treatment that has allowed thousands of men with low-risk prostate cancer to avoid or delay therapy by monitoring it closely instead of immediately treating it.
Now Klotz has launched a new clinical trial called PRECISE, funded with $3 million in support by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada, that will use MRI to help to better diagnose prostate cancer without invasive biopsy.